AI Article Synopsis

  • The Patient Health Questionnaire-9 (PHQ-9) is a commonly used tool for screening major depressive disorder (MDD), but it can sometimes miss or misdiagnose cases.
  • A new nomogram was developed using data from premature ejaculation patients to improve screening accuracy by considering the severity of depressive symptoms.
  • This nomogram demonstrated better calibration and discriminatory capacity than the PHQ-9 during a study involving 1,066 participants, potentially reducing the chances of missed or incorrect MDD diagnoses in various populations.

Article Abstract

Patient Health Questionnaire-9 (PHQ-9) is the most widely used tool for screening for major depressive disorder (MDD). Although its reliability and validity have been proven, missed or misjudged cases during MDD screening are often encountered. A nomogram that considers the weights of depressive symptoms was developed using data from premature ejaculation patients to improve screening accuracy. During a 33-month prospective study, a training cohort comprising 605 participants from Xijing Hospital was used to develop and internally validate the nomogram. A validation cohort comprising 461 patients from Xi'an Daxing Hospital was also used to externally test the nomogram. The nomogram was established by integrating the LASSO regression-based optimal predictors of MDD according to their coefficients in a multivariate logistic regression model. The nomogram was well-calibrated during internal and external validations. Moreover, it showed a better discriminatory capacity and yielded more net benefits in both validations than PHQ-9. With better performance, the nomogram may help reduce the number of missed or misjudged cases during MDD screening. This study is the first to weigh the direct indicators of MDD under the DSM-5 criteria, presenting a fresh concept that can be applied to other populations to enhance screening accuracy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2023.115277DOI Listing

Publication Analysis

Top Keywords

major depressive
8
depressive disorder
8
prospective study
8
missed misjudged
8
misjudged cases
8
cases mdd
8
mdd screening
8
screening accuracy
8
cohort comprising
8
screening
6

Similar Publications

Efficacy of probiotic adjuvant therapy in women with major depressive disorder: insights from a case series study.

Pharmacol Rep

January 2025

Laboratory of Translational Physiology and Pharmacology, Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), R Mercurio s/n, Vila Velha, ES, 29102623, Brazil.

Background: The therapeutic targeting of the intestinal microbiota has gained increasing attention as a promising avenue for addressing mood disorders. This study aimed to assess the potential effect of supplementing standard pharmacological treatment with the probiotic kefir in patients with Major Depressive Disorder (MDD).

Methods: Thirty-eight female participants diagnosed with moderate MDD by the Hamilton Rating Scale for Depression (HAM-D) were selected to receive the probiotic kefir in conjunction with antidepressant therapy for 12 weeks.

View Article and Find Full Text PDF

Introduction: Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder among children with attention deficit hyperactivity disorder (ADHD). This study aims to determine the prevalence of OSA in children with ADHD, compare the differences in clinical characteristics between children with ADHD-OSA and those without OSA (ADHD-nonOSA), and to identify the correlation between OSA and ADHD in children.

Methods: This cross-sectional descriptive study was conducted on 524 children with ADHD, aged 6-12 years, at the Vietnam National Children's Hospital from October 2022 to September 2023.

View Article and Find Full Text PDF

Obstructive sleep apnea (OSA), a highly prevalent and serious disorder with significant complications, causes considerable daytime and nighttime symptoms as well as long-term consequences and is yet an underdiagnosed and inadequately treated condition. Patients with OSA undergo frequent awakenings during the sleep cycle and find it impossible to get restorative sleep. Individuals are extremely fatigued, sleepy, and irritable throughout the day.

View Article and Find Full Text PDF

Placebo effect represents a serious confounder for the assessment of treatment effect to the extent that it has become increasingly difficult to develop antidepressant medications appropriate for outperforming placebo. Treatment effect in randomized, placebo-controlled trials, is usually estimated by the mean baseline adjusted difference of treatment response in active and placebo arms and is function of treatment-specific and non-specific effects. The non-specific treatment effect varies subject by subject conditional to the individual propensity to respond to placebo.

View Article and Find Full Text PDF

Identifying genetic differences between bipolar disorder and major depression through multiple genome-wide association analyses.

Br J Psychiatry

January 2025

Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, USA; Department of Human Genetics, University of California Los Angeles, USA; and Department of Computational Medicine, University of California Los Angeles, USA.

Background: Accurate diagnosis of bipolar disorder (BPD) is difficult in clinical practice, with an average delay between symptom onset and diagnosis of about 7 years. A depressive episode often precedes the first manic episode, making it difficult to distinguish BPD from unipolar major depressive disorder (MDD).

Aims: We use genome-wide association analyses (GWAS) to identify differential genetic factors and to develop predictors based on polygenic risk scores (PRS) that may aid early differential diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!